If you blinked, you might’ve missed it—but fashion moved fast this week. Louis Vuitton announced Chase Infiniti as their ...

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the following medicines and indications have been renewed in ...

Zai Bennett also told Content London that "it's challenging out there," including financing challenges for the TV industry.

Zai Lab Ltd (NASDAQ:ZLAB) reported its Q3 2025 earnings, revealing an adjusted loss per share of $0.33, missing the forecast of $0.25. Revenue reached $116.1 million, falling short of the anticipated ...

Zai Lab (ZLAB), a $3.3B market cap Chinese pharmaceutical company, is growing revenues at 40%+ and positioned to benefit from the country’s rapidly aging demographics. With China expected to undergo a ...

The "Rule of 10" is a widely accepted yardstick within the biopharma industry for the chances of commercial success. According to the adage, it takes around 10 years and $1 billion to develop a viable ...

Amgen's bemarituzumab trial has taken a turn, with a final analysis showing weaker survival benefits than previously found in an earlier pre-specified interim analysis. In June, Amgen and China ...

- Newly formed Advisory Board comprises world-class leaders in oncology to support advancement of Zai Lab’s robust oncology products and pipeline SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab ...

When Apple introduced “spatial audio” to Apple Music and the AirPods family, it quickly became a bigger buzzword in audio discussions. In just a few years, it has become ubiquitous. This popularity ...

Zai Lab Limited is an innovative Pharma partnering with US and European Pharmas to secure approvals for, and market their drugs in China. ZLAB stock has surged over 105% in the past year, driven by ...

Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter ...